Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTI 03

Next Previous
Drug Profile

LTI 03

Alternative Names: Caveolin-1 scaffold protein-derived 7-amino acid peptide; Caveolin-1 scaffolding protein derived peptide; CSP7; LTI-03

Latest Information Update: 14 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Developer Rein Therapeutics; University of Texas at Tyler
  • Class Alcohols; Amides; Amino acids; Antifibrotics; Benzene derivatives; Carboxylic acids; Peptides
  • Mechanism of Action Caveolin 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 06 Nov 2025 Updated efficacy and adverse event data from a phase Ib trial in Idiopathic pulmonary disease released by Rein Therapeutics
  • 03 Nov 2025 US FDA lifts a clinical hold on LTI 03 for the treatment of Idiopathic pulmonary fibrosis
  • 09 Oct 2025 The European Medicines Agency (EMA) grants authorization to initiate the phase II RENEW trial in Germany and Poland

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top